Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Short Interest Up 301.8% in August

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) saw a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 66,541 shares, an increase of 301.8% from the July 30th total of 16,560 shares. Based on an average daily volume of 1,169 shares, the short-interest ratio is currently 56.9 days.

Neuren Pharmaceuticals Price Performance

NURPF opened at C$16.24 on Friday. The company’s 50-day moving average is C$13.55 and its 200 day moving average is C$10.44. Neuren Pharmaceuticals has a fifty-two week low of C$7.70 and a fifty-two week high of C$17.25.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.